														CIC	OMS	F	ORI
SUSPECT ADVERSE REACTION REPORT																	
000120	JI ADVENOL I	KEAGIION KEI O	111						_	_		_	_				_
I. REACTION INFORMATION																	
1. PATIENT INITIALS	1a. COUNTRY	2. DATE OF BIRTH	2a. AGE	3. SEX	3a. WEIGHT	1	6 RE	ACTION	NONS	SET	8-12			CK ALL			
(first, last) PRIVACY	COSTA RICA	Day PRIVACY Year	Unk	Male	Unk	Day	′	Month Unk		Year] -	A	ADVE	ROPRIA ERSE R ENT DIE	EACTI	ON	
7 + 13 DESCRIBE REAC Event Verbatim [PREFER Bad fasting gluco occasional hypog								INVOLVED OR PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT OR SIGNIFICANT									
Case Description: ***This is an auto generated narrative***											OR SIGNIFICANT DISABILITY OR INCAPACITY						
This non-serious Spontaneous case from COSTA RICA was reported by a Consumer as "Bad fasting glucc control (increases)(Fasting blood glucose increased)" with an unspecified onset date, "occasional								ose	LIFE THREATENING								
hypoglycemia(Hypoglycemia)" with an unspecified onset date, and concerned a Adult Male patient who was treated with Tresiba FlexTouch (Insulin Degludec) from								-	CONGENITAL ANOMALY								
troated with 11001	(Continued on Additional Information Page)																
		II. SUSPEC	T DRU	JG(S) IN	FORMA	TIOIT	N										
14. SUSPECT DRUG(S) (include generic name) #1) Tresiba FlexTouch (Insulin Degludec) Solution for injection					(Continued on Additional Information Page)							20. DID REACTION ABATE AFTER STOPPING DRUG?					
					ROUTE(S) OF ADMINISTRATION) Unknown						YES NO NA						
17. INDICATION(S) FOR #1) Product used	(Cont	(Continued on Additional Information Page)							21. DID REACTION REAPPEAR AFTER REINTRODUCTION?								
` '					THERAPY DURATION) Unknown							YES NO NA					
		III. CONCOMIT	TANT [DRUG(S) AND H	ISTO	OR'	Y									
22. CONCOMITANT DRU	JG(S) AND DATES OF ADM	IINISTRATION (exclude those us	sed to treat r	eaction)													
23. OTHER RELEVANT I	HISTORY. (e.g. diagnostics,	allergies, pregnancy with last mo	onth of perio	d, etc.) Description													
Unknown to Ongo	oing	Current Condition		Diabetes	(Diabetes	melli	itus))									
Type and duration not reported.																	
		IV. MANUF	ACTU			ION	1										
24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S				26. REM	ally Confirr	ned: N	No										
Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888																	
	24b. MFR CC	INTROL NO.		25h NA	ME AND ADDE	RESS O	FRF	PORTE	R								
	1439774				25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.												
24c. DATE RECEIVED BY MANUFACTURE	24d. REPORT	SOURCE LITERATURE		\neg													
20-MAY-2025	HEALTH	Ш	aneous														
DATE OF THIS REPORT 23-JUN-2025	25a. REPOR	T TYPE FOLLOWUP:															

Mfr. Control Number: 1439774

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

unknown start date and ongoing for "Product used for unknown indication",

Dosage Regimens: Tresiba FlexTouch:

Current Condition: Diabetes.

Batch Numbers:

Tresiba FlexTouch: ASKU

Action taken to Tresiba FlexTouch was reported as No Change.

The outcome for the event "Bad fasting glucose control (increases)(Fasting blood glucose increased)" was Not Reported. The outcome for the event "occasional hypoglycemia(Hypoglycemia)" was Not Reported.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Tresiba FlexTouch (Insulin Degludec)	UNK; Unknown	Product used for unknown	Ongoing;
Solution for injection; Regimen #1		indication (Product used for	Unknown
		unknown indication)	